Key result
Dexmedetomidine infusion during congenital cardiac surgery significantly reduced pulmonary artery systolic pressure compared to placebo (25.3 vs 44.29 mmHg after sternotomy, p<0.001) in pediatric patients with pulmonary hypertension.
Why the study?
Anesthetized patient management for pediatric patients with pulmonary arterial hypertension is a major challenge, and the ability of dexmedetomidine to reduce pulmonary arterial hypertension during cardiac surgery required evaluation.
Does dexmedetomidine reduce pulmonary artery systolic pressure in pediatric patients with pulmonary arterial hypertension undergoing congenital heart surgery?
RCT (n=66)
Double-blind
Computer-generated randomized sequence
No
Does dexmedetomidine reduce pulmonary artery systolic pressure in pediatric patients with pulmonary arterial hypertension undergoing congenital heart surgery?
Absolute Event Rate: 25.3% vs 44.29%
p-value: p=<0.001
Intraoperative and postoperative dexmedetomidine infusion significantly reduces pulmonary artery systolic pressure and the need for vasodilators and sedatives in pediatric patients with pulmonary hypertension undergoing congenital heart surgery.
Authors
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for dexmedetomidine in pediatric pulmonary hypertension; prospective randomized trials needed before clinical adoption.
Ghasemzadeh et al. (2020) conducted an RCT in Pulmonary arterial hypertension in congenital heart disease (n=66). Dexmedetomidine vs. Normal saline 0.9% was evaluated on Pulmonary artery systolic pressure (PASP) after sternotomy (p=<0.001). Dexmedetomidine infusion during congenital cardiac surgery significantly reduced pulmonary artery systolic pressure compared to placebo (25.3 vs 44.29 mmHg after sternotomy, p<0.001) in pediatric patients with pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: